Irbepress-Hct

Irbesartan/Hydrochlorothiazide, the active ingredient in Irbepress-Hct, is an angiotensin II receptor blocker combined with a thiazide diuretic, presented as an oral tablet formulation. It is used to lower elevated blood pressure in adult patients with hypertension, often when monotherapy is insufficient.

GNH USA supplies Irbepress-Hct as a licensed, Good Distribution Practice‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide under regulated quality standards. The company ensures batch consistency and compliance with strict EU marketing authorisation requirements.

Irbepress-Hct combines an angiotensin II receptor blocker with a thiazide diuretic and is used to manage conditions related to elevated blood pressure.

- Hypertension: lowers systolic and diastolic blood pressure in adult patients. - Hypertensive edema: reduces fluid accumulation associated with high blood pressure. - Hypertension in type 2 diabetes: assists in blood pressure control while providing modest renal protection.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pain in the head region. - Increased urination: more frequent need to void due to diuretic action. - Electrolyte imbalance (low potassium): reduced serum potassium levels. - Fatigue: general feeling of tiredness or lack of energy.

Serious or Rare Side Effects: - Severe dehydration: excessive fluid loss leading to low blood pressure. - Acute kidney injury: sudden decline in renal function. - Hyperkalemia: dangerously high potassium levels. - Anaphylactic reaction: severe allergic response requiring emergency care. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain.

Before initiating therapy, consider the following precautions: - Monitor blood pressure: ensure target levels are achieved without excessive drop. - Assess renal function: check serum creatinine and eGFR periodically. - Check electrolytes: especially potassium and sodium levels. - Use caution in hepatic impairment: dose adjustments may be required. - Avoid in severe hypotension: the drug can further lower blood pressure. - Store at room temperature: keep in the original pack, protect from moisture.

Irbepress-Hct may interact with several medicines; awareness helps avoid adverse outcomes.

Major Interactions (Avoid): - Aliskiren: combined renin‑angiotensin blockade can cause renal impairment. - Potassium‑sparing diuretics (e.g., spironolactone): risk of hyperkalemia. - NSAIDs: may blunt antihypertensive effect and affect kidney function. - Lithium: increased lithium levels and toxicity. - ACE inhibitors: additive risk of hypotension and renal dysfunction.

Moderate Interactions (Monitor Closely): - Other thiazide diuretics: additive diuretic effect may cause electrolyte loss. - Antidiabetic agents: blood‑glucose may decrease, requiring dose adjustment. - Antacids containing aluminum/magnesium: may reduce absorption of irbesartan. - CYP2C9 inhibitors (e.g., fluconazole): can raise irbesartan plasma concentrations. - Beta‑blockers: combined effect may lead to excessive blood‑pressure reduction.